September 16, 2014 11:47 AM ET

Life Sciences Tools and Services

Company Overview of Profil Institute for Clinical Research, Inc.

Company Overview

Profil Institute for Clinical Research, Inc. provides early phase clinical research services in diabetes and obesity. It guides the developmental planning, design, and actual performance of early phase clinical studies, and helps its clients in the determination of whether a new compound should be carried forward into the later phases of clinical development. Profil Institute for Clinical Research, Inc. has a strategic alliance with Rosa & Co. LLC; and a strategic collaboration with DiaVacs, Inc. The company was founded in 2004 and is based in Chula Vista, California.

855 3rd Avenue

Suite 4400

Chula Vista, CA 91911

United States

Founded in 2004

Phone:

619-427-1300

Fax:

619-427-1307

Key Executives for Profil Institute for Clinical Research, Inc.

Chief Executive Officer
Editor-In-Chief
Chief Operating Officer
Director of Pharmaceutical Services
Associate Director of Corporate Communications
Compensation as of Fiscal Year 2014.

Profil Institute for Clinical Research, Inc. Key Developments

DiaVacs Announces Strategic Collaboration with Profil Institute to Conduct Phase IB/IIA Randomized Clinical Trial of New Cell-Based Therapy for Type 1 Diabetes

DiaVacs, Inc. and Profil Institute for Clinical Research, Inc. announced a strategic collaboration to conduct DiaVacs' phase Ib/IIa clinical trial. This clinical trial will study the safety and preliminary efficacy of DiaVacs' novel dendritic cell therapy for treatment of type 1 diabetes in patients who are newly diagnosed. DiaVacs' proprietary technology is based on dendritic cell therapy. DiaVacs has perfected the immunology and technology to take a patient's own dendritic cells from their blood, modify them through the use of small interfering oligonucleotides, and then vaccinate the patient by simple injection of these modified cells under the skin using a small needle. The cells are taken up and trafficked to the pancreatic lymph nodes where they take up residence and induce tolerance. This cell-based therapy has been shown to be safe in phase I human trials and effective at halting disease progression in preclinical models of disease. The double-blind, placebo-controlled study will begin by first enrolling 10 subjects who are at least 18 years of age with newly diagnosed type 1 diabetes (< 6 months from diagnosis). A fifteen month commitment will be required of all study participants, including multiple visits to Profil Institute's San Diego clinical facility. Thereafter, the study will expand the inclusion criteria to include younger participants who are newly diagnosed. The primary efficacy endpoint of the study is evidence of the return of insulin secretion by the pancreas. Additionally, various immune markers will be assessed for evidence that the autoimmune process responsible for type 1 diabetes has been altered.

Profil Institute Announces Board Appointments

Profil Institute for Clinical Research, Inc. announced the appointment of Dan Bradbury, Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO, to its Board of Directors. Mr. Bradbury joins Profil Institute's current Board Directors Dr. John Amatruda, a pharmaceutical research executive and former Senior Vice President and Head of Diabetes and Obesity at Merck Research Laboratories; Dr. Jerrold Olefsky, Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine; Dr. Linda Morrow, Profil Institute's COO; and Dr. Marcus Hompesch, Profil Institute's President and CEO. Mr. Bradbury is a life sciences executive with over 30 years of experience creating and implementing strategies that transform businesses and bring novel medicines to market. He is currently Managing Member of BioBrit, LLC, a life sciences consulting and investment firm. Prior to that, Mr. Bradbury served as Amylin Pharmaceuticals' President, Chief Executive Officer and Director from 2007 until its acquisition by Bristol-Myers Squibb Company in 2012. Mr. Bradbury serves on the Board of Directors of Corcept Therapeutics, Geron Corporation, Illumina, Inc., BioMed Realty, Biocon Limited, Castle Biosciences, Inc. (Private), DiaVacs (Private) and Microdermis, Inc. (Private). He also serves on the Board of Trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee. In addition to his Board positions, Mr. Bradbury serves on the University of California San Diego's Rady School of Management's Advisory Council and the University of Miami's Innovation Corporate Advisory Council.

Profil Institute for Clinical Research, Inc. Appoints Andrew J Krentz as Editor-in-Chief of the Online Journal Cardiovascular Endocrinology

Profil Institute for Clinical Research, Inc. announced that Prof. Andrew J Krentz M.D., Senior Director of Scientific Services, has been appointed Editor-in-Chief of the online journal Cardiovascular Endocrinology. The journal was officially launched this week at the European Association for the Study of Diabetes (EASD) meeting in Berlin.

Similar Private Companies By Industry

Company Name Region
KP Pharmaceutical Technology Inc. United States
Johnston, Zabor, McManus, Inc. United States
Photometrics United States
Blue Sky Biotech, Inc. United States
Progenitor Cell Therapy, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Profil Institute for Clinical Research, Inc., please visit www.profil-research.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.